Open AccessMaintenance Therapy for First‐Line Metastatic Colorectal Cancer: Activity and Sustainability
Author(s) -
Strickler John H.,
Hurwitz Herbert I.
Publication year - 2012
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2011-0358
Subject(s) - medicine , bevacizumab , capecitabine , oxaliplatin , colorectal cancer , oncology , regimen , cancer , chemotherapy
Results of a study, published in this issue of The Oncologist , comparing capecitabine and oxaliplatin plus bevacizumab with the same regimen for only six cycles followed by bevacizumab monotherapy in metastatic colorectal cancer patients are examined.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom